In March, the US Food and Drug Administration (FDA) granted Cereno Scientific’s preclinical candidate CS-1 (valproic acid) Orphan Drug Designation for pulmonary arterial hypertension.

GlobalData supposes that CS-1 could fill a gap in the market due to its innovative mechanism of action, particularly epigenetic modulation of cardiovascular disease by histone deacetylase inhibition.